Click here to close now.




















Welcome!

News Feed Item

Moderna Announces $40 Million In Financing To Advance Development Of New Biotherapeutic Modality: Messenger RNA Therapeutics™

Company announces appointment of Executive Leadership Team and Scientific Advisory Board

CAMBRIDGE, Mass., Dec. 6, 2012 /PRNewswire/ -- Moderna Therapeutics announced today that it has closed more than $40 million in financing to date, led by Flagship Ventures and private investors, which will be used to advance multiple programs toward clinical stage development. Moderna is pioneering messenger RNA Therapeutics™, a novel biotherapeutic modality with the unprecedented capability of stimulating the body's natural ability to produce therapeutic proteins. If successful in human clinical trials, this advance will usher in the first entirely new way of making therapeutic proteins since the development of recombinant technology more than 30 years ago, with dramatic implications for both patients and industry.

Moderna was founded within Flagship VentureLabs, an innovation foundry dedicated to institutional entrepreneuring. Over the past 18 months, Moderna has conducted proof-of-concept studies in preclinical models, including non-human primates, and has demonstrated the ability to induce in vivo production of dozens of intracellular and secreted therapeutic proteins through intramuscular, subcutaneous or intravenous administration across multiple preclinical models. The company anticipates publishing and presenting the results of these studies in 2013.

Moderna has appointed an accomplished executive leadership team and scientific advisory board, and implemented a comprehensive intellectual property strategy surrounding messenger RNA Therapeutics, filing over 80 patent applications reciting more than 4,000 claims covering novel chemical modifications, RNA engineering, formulation, composition of matter, route of administration and dosing. The company has established preclinical programs in four key therapeutic areas: oncology supportive care, inherited genetic disorders, hemophilia and diabetes.

"Our messenger RNA Therapeutics platform has the potential to revolutionize the treatment of a wide variety of illnesses by opening up a completely new biotherapeutic modality, and by offering a technologically and financially superior path for the discovery, creation and endogenous production of therapeutic proteins," said Stephane Bancel, president and founding CEO of Moderna. "In the last 18 months, we have charged ahead in this space, vigorously pursuing a robust IP portfolio. We have hired an experienced employee base and cultivated leadership and advisory teams who are offering deep insights as we advance key programs into clinical development. We are working with great urgency and great care to translate this groundbreaking science into new treatments for patients."

Moderna's Leadership Team

Before joining Moderna, Bancel served for five years as the CEO of bioMerieux, a world leader in diagnostics, where he led the company through 10 successful acquisitions in the U.S., Europe and Asia/Pacific; nearly doubled the company's sales growth rate to above nine percent per year; and doubled the company's market capitalization despite the 2008 global financial crisis. Prior to his time at bioMerieux, Stephane was Managing Director of Eli Lilly in Belgium and Executive Director of Global Manufacturing Strategy and Supply Chain at Eli Lilly in Indianapolis, Indiana. He started at Lilly in its UK manufacturing plant outside London. Before joining Lilly he also served as Asia-Pacific Sales and Marketing Director for bioMerieux while based in Tokyo. He holds a Master of Engineering from Ecole Central Paris, a Master of Science in Chemical Engineering from the University of Minnesota and an MBA from Harvard Business School, and is named as an inventor on more than 45 patent filings in the field of messenger RNA (mRNA) technology.

Bancel has assembled a seasoned executive team composed of biotech and pharmaceutical professionals who have played key roles in successfully developing and commercializing biotech products. Susan Whoriskey, Ph.D., senior vice president of technology strategy, served on the founding executive teams of Momenta Pharmaceuticals and Cubist Pharmaceuticals. Chief scientific officer Tony de Fougerolles, Ph.D., brings more than 15 years of research and development experience to this role, having served previously as chief scientific officer at Tolerx, and on the management team at Alnylam Pharmaceuticals as vice president of research for immunology, metabolic and viral disease. Louis O'Dea, MB, BCh, BAO, chief medical officer and head of regulatory affairs, previously led clinical and regulatory activities at Radius Health and was worldwide head of clinical development for reproductive health and metabolism at Serono.

Moderna's leadership is supported by an engaged and experienced board of directors, chaired by Noubar Afeyan, Ph.D., co-founder of Moderna, and also co-founder, managing partner and CEO of Flagship Ventures, a leading early-stage venture capital firm. Dr. Afeyan is joined on the board by: Robert Carpenter, President, Boston Medical Investors, Inc.; Peter Barton Hutt, Senior Counsel, Covington & Burling; Robert Langer, Sc.D., David H. Koch Institute Professor at MIT; John Mendlein, Ph.D., Executive Chairman and CEO of aTyr Pharma; Derrick Rossi, Ph.D., assistant professor in the Stem Cell Regenerative Biology Department at Harvard Medical School and Harvard University; and Timothy Springer, Ph.D., Latham Family Professor at Harvard Medical School and Professor of Medicine at Children's Hospital Boston. Board members Robert Langer and Derrick Rossi are academic co-founders of Moderna, along with scientific advisory board member Kenneth Chien from Harvard University.

"Moderna's promise rivals that of the earliest biotechnology companies over 30 years ago -- adding an entirely new drug category to the pharmaceutical arsenal in the fight against important diseases," said Noubar Afeyan, co-founder and chairman of Moderna. "The executive team, board of directors and scientific advisors all combine the expertise and passion needed to create an unparalleled company that fits the extraordinary scope of this opportunity," he added.

Moderna has assembled a scientific advisory board of world-renowned experts led by Jack Szostak, Ph.D.,2009 winner of the Nobel Prize in medicine, Howard Hughes Medical Institute investigator, professor of genetics at Harvard Medical School and Alex Rich Distinguished Investigator, Department of Molecular Biology at the Center for Computational and Integrative Biology at Massachusetts General Hospital. The scientific advisory board also includes Douglas Cole, MD, General Partner, Flagship Ventures; Kenneth Chien, MD, Ph.D., professor in the Department of Cell and Molecular Biology and Department of Medicine at the Karolinska Institute, and visiting professor in the Department of Stem Cell and Regenerative Biology, Harvard University.; David Liu, Ph.D., Professor of Chemistry and Chemical Biology at Harvard University, a Howard Hughes Medical Institute Investigator and a Senior Associate Member of the Broad Institute of Harvard and MIT; Douglas Melton, Ph.D., Thomas Dudley Cabot Professor in the Natural Sciences at Harvard University and an Investigator of the Howard Hughes Medical Institute; Elizabeth Nabel, MD, President of the Brigham and Women's Hospital (BWH) and Professor of Medicine, Harvard Medical School; and Ulrich H. von Andrian, M.D., Mallinckrodt Professor of Immunopathology at Harvard Medical School. Board members Robert Langer, Derrick Rossi and Timothy Springer also sit on the scientific advisory board.  

About Moderna   
Moderna is pioneering messenger RNA Therapeutics™, an entirely new treatment modality that enables the body to produce therapeutic proteins in vivo. Moderna is using this approach to develop first-ever treatments for a wide range of diseases that cannot be addressed today using existing technologies, and to drastically reduce the time and expense associated with creating therapeutic proteins using recombinant technologies. The company has demonstrated proof-of-concept using messenger RNA Therapeutics for a variety of indications and is moving multiple programs into the clinic. Visit www.modernatx.com to learn more.

Contact: Jessica Rowlands
Phone: 202-729-4089
Email: [email protected] 

SOURCE Moderna Therapeutics

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
WebRTC has had a real tough three or four years, and so have those working with it. Only a few short years ago, the development world were excited about WebRTC and proclaiming how awesome it was. You might have played with the technology a couple of years ago, only to find the extra infrastructure requirements were painful to implement and poorly documented. This probably left a bitter taste in your mouth, especially when things went wrong.
Whether you like it or not, DevOps is on track for a remarkable alliance with security. The SEC didn’t approve the merger. And your boss hasn’t heard anything about it. Yet, this unruly triumvirate will soon dominate and deliver DevSecOps faster, cheaper, better, and on an unprecedented scale. In his session at DevOps Summit, Frank Bunger, VP of Customer Success at ScriptRock, will discuss how this cathartic moment will propel the DevOps movement from such stuff as dreams are made on to a prac...
Cloud and datacenter migration innovator AppZero has joined the Microsoft Enterprise Cloud Alliance Program. AppZero is a fast, flexible way to move Windows Server applications from any source machine – physical or virtual – to any destination server, in any cloud or datacenter, using its patented container technology. AppZero’s container is also called a Virtual Application Appliance (VAA). To facilitate Microsoft Azure onboarding, AppZero has two purpose-built offerings: AppZero SP for Azure,...
WSM International, the pioneer and leader in server migration services, has announced an agreement with WHOA.com, a leader in providing secure public, private and hybrid cloud computing services. Under terms of the agreement, WSM will provide migration services to WHOA.com customers to relocate some or all of their applications, digital assets, and other computing workloads to WHOA.com enterprise-class, secure cloud infrastructure. The migration services include detailed evaluation and planning...
This Enterprise Strategy Group lab validation report of the NEC Express5800/R320 server with Intel® Xeon® processor presents the benefits of 99.999% uptime NEC fault-tolerant servers that lower overall virtualized server total cost of ownership. This report also includes survey data on the significant costs associated with system outages impacting enterprise and web applications. Click Here to Download Report Now!
IBM’s Blue Box Cloud, powered by OpenStack, is now available in any of IBM’s globally integrated cloud data centers running SoftLayer infrastructure. Less than 90 days after its acquisition of Blue Box, IBM has integrated its Blue Box Cloud Dedicated private-cloud-as-a-service into its broader portfolio of OpenStack® based solutions. The announcement, made today at the OpenStack Silicon Valley event, further highlights IBM’s continued support to deliver OpenStack solutions across all cloud depl...
Consumer IoT applications provide data about the user that just doesn’t exist in traditional PC or mobile web applications. This rich data, or “context,” enables the highly personalized consumer experiences that characterize many consumer IoT apps. This same data is also providing brands with unprecedented insight into how their connected products are being used, while, at the same time, powering highly targeted engagement and marketing opportunities. In his session at @ThingsExpo, Nathan Trel...
SYS-CON Events announced today that Pythian, a global IT services company specializing in helping companies leverage disruptive technologies to optimize revenue-generating systems, has been named “Bronze Sponsor” of SYS-CON's 17th Cloud Expo, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Founded in 1997, Pythian is a global IT services company that helps companies compete by adopting disruptive technologies such as cloud, Big Data, advance...
While many app developers are comfortable building apps for the smartphone, there is a whole new world out there. In his session at @ThingsExpo, Narayan Sainaney, Co-founder and CTO of Mojio, will discuss how the business case for connected car apps is growing and, with open platform companies having already done the heavy lifting, there really is no barrier to entry.
SYS-CON Events announced today that HPM Networks will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. For 20 years, HPM Networks has been integrating technology solutions that solve complex business challenges. HPM Networks has designed solutions for both SMB and enterprise customers throughout the San Francisco Bay Area.
SYS-CON Events announced today that G2G3 will exhibit at SYS-CON's @DevOpsSummit Silicon Valley, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Based on a collective appreciation for user experience, design, and technology, G2G3 is uniquely qualified and motivated to redefine how organizations and people engage in an increasingly digital world.
SYS-CON Events announced today the Containers & Microservices Bootcamp, being held November 3-4, 2015, in conjunction with 17th Cloud Expo, @ThingsExpo, and @DevOpsSummit at the Santa Clara Convention Center in Santa Clara, CA. This is your chance to get started with the latest technology in the industry. Combined with real-world scenarios and use cases, the Containers and Microservices Bootcamp, led by Janakiram MSV, a Microsoft Regional Director, will include presentations as well as hands-on...
Through WebRTC, audio and video communications are being embedded more easily than ever into applications, helping carriers, enterprises and independent software vendors deliver greater functionality to their end users. With today’s business world increasingly focused on outcomes, users’ growing calls for ease of use, and businesses craving smarter, tighter integration, what’s the next step in delivering a richer, more immersive experience? That richer, more fully integrated experience comes ab...
SYS-CON Events announced today that Micron Technology, Inc., a global leader in advanced semiconductor systems, will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Micron’s broad portfolio of high-performance memory technologies – including DRAM, NAND and NOR Flash – is the basis for solid state drives, modules, multichip packages and other system solutions. Backed by more than 35 years of tech...
Everyone talks about continuous integration and continuous delivery but those are just two ends of the pipeline. In the middle of DevOps is continuous testing (CT), and many organizations are struggling to implement continuous testing effectively. After all, without continuous testing there is no delivery. And Lab-As-A-Service (LaaS) enhances the CT with dynamic on-demand self-serve test topologies. CT together with LAAS make a powerful combination that perfectly serves complex software developm...